Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1214)	3/5/2004 9:16:32 AM
From: software salesperson	Respond to of 1834

3/4/04 lehman brothers no slides sleep maintenance : for middle of the night awakenings; a unique study; I has advantage due to short ½ life, so can take at 3 am ; no tolerance issues re: efficacy at 4 weeks vis-à-vis 1 week sleep mtn. is one competitive differentiator for I to existing and potential new drugs also, for sleep mtn., 1 hr. improvement(reduction) in WASO is greater than others in development didn’t say what % of patient population had this problem long-term treatment : = removal of short-term restriction( there’s the answer to my question of the other day); now saying that fda guidelines for long-term label require 100 patients to have received 12 months of treatment, rather than previously saying that 2 long-term trials were needed- - hmmmm sales